Age

18–any

Sex

FEMALE

Healthy volunteers

Not accepted

Voluntary participation and written informed consent.
≥18 years;
Histologically confirmed epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
Confirmed platinum-resistant relapse.
According to RECIST 1.1 criteria, there must be at least one measurable lesion in the baseline.
Expected survival of more than 3 months.
ECOG performance status score of 0 or 1.
Adequate organ function.
Capable and willing to comply with the study protocol, treatment plan, laboratory tests, and other related study procedures.

Primary platinum-refractory disease.
Active central nervous system metastases.
Uncontrolled pleural effusion.
Previous treatment with topoisomerase I inhibitor ADCs.
Other malignant tumors within 5 years.
Interstitial pneumonia/lung disease requiring systemic corticosteroids or suspected interstitial pneumonia/lung disease.
Uncontrolled comorbidities.
Toxicity from previous anti-cancer treatments not recovered to CTCAE Grade ≤1.
History of allogeneic bone marrow or organ transplantation.
Allergic reactions or hypersensitivity to antibody drugs.
Conditions affecting study drug treatment safety or compliance, including psychiatric disorders, alcohol abuse, or drug abuse.

JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer